Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

@article{Bibbiani2001Serotonin5A,
  title={Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models},
  author={Francesco Bibbiani and J. D. Oh and Thomas N. Chase},
  journal={Neurology},
  year={2001},
  volume={57},
  pages={1829 - 1834}
}
Background: Serotoninergic transmission in the basal ganglia is known to influence dopaminergic mechanisms and motor function. Objective: To evaluate the possibility that serotoninergic 5-HT1A autoreceptors (by regulating the release of serotonin as well as dopamine formed from exogenous levodopa) affect the response alterations complicating levodopa treatment of PD. Methods: The 5-HT1A receptor agonist sarizotan (EMD128130) was systemically administered alone and together with levodopa to… Expand
Quetiapine Attenuates Levodopa-Induced Motor Complications in Rodent and Primate Parkinsonian Models
TLDR
The results suggest that quetiapine could confer therapeutic benefits to patients with levodopa-induced motor complications and may indicate that 5HT2A/C receptor-mediated mechanisms, alone or in combination with other mechanisms, contribute to the pathogenesis of the altered motor responses associated with the treatment of PD. Expand
5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation
TLDR
Pre-clinical data suggest that simultaneous activation of 5- HT1A and 5-HT1B receptors induced a potent synergistic effect on suppression of dyskinesia, which is the most problematic side effect during chronic L-DOPA treatment in parkinsonian patients. Expand
Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease
TLDR
It is suggested that 5‐HT1A receptor stimulation in levodopa‐treated parkinsonian patients can modulate striatal dopaminergic function and that 5-HT2A agonists may be useful as levodOPA adjuvants in the treatment of PD. Expand
Serotonin 1A receptor agonist modulation of motor deficits and cortical oscillations by NMDA receptor interaction in parkinsonian rats
TLDR
It is suggested that 8-OH-DPAT administration ameliorates motor symptoms of PD through glutamatergic rather than the dopaminergic pathway and improves motor activity and modulates the oscillations in the motor cortex of parkinsonian rats. Expand
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease
TLDR
The results suggest that KW-6002 can attenuate the induction as well as the expression of motor response alterations to chronic dopaminergic stimulation in parkinsonian animals, possibly by blocking A(2A) receptor-stimulated signaling pathways. Expand
The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat
TLDR
The present findings indicate that 5-HT(1A)R stimulation reduces AIMs induced by D1R, D2R and l-DOPA administration while its effects on DA agonist-induced rotations were receptor-dependent, suggesting that direct 5- HT(1 a)R and DA receptor interactions may contribute to the unique profile of 5-ht(1a)R agonists for the improvement of PD treatment. Expand
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat
TLDR
Combined subthreshold doses of ±8-OH-DPAT and MK-801 dose-dependently decreased l-DOPA-induced AIMs without affecting rotations and indicate a functional interaction between 5-HT1AR and NMDAR that may improve pharmacological treatment of PD patients. Expand
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats
TLDR
Results suggest that the STN is a target structure for the antidyskinetic action of sarizotan and indicate that drug-mediated modulation of STN activity may be an alternative option for the treatment of levodopa-induced dyskinesias in Parkinson’s disease. Expand
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to l-DOPA in a rodent model of Parkinson's disease
Marked fluctuation of dopamine concentration in the striatum following long-term L-DOPA administration contributes to the development of L-DOPA-induced motor complications including L-DOPA-inducedExpand
Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
TLDR
An involvement of D3 receptors in the action of sarizotan on some, but not all l-DOPA-induced motor side effects is identified, in contrast to the more general involvement of 5-HT1A receptor in the anti-dyskinetic effects of sarzotan. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
TLDR
AMPA receptor upregulation may contribute to the expression of levodopa-induced dyskinesia, and noncompetitive AMPA receptor antagonists could be useful, alone or in combination with NMDA antagonists, in the treatment of PD, by enhancing the antiparkinsonian effects oflevodopa without increasing and possibly even decreasing levodOPA-induced Dyskineia. Expand
Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat
  • M. Wadenberg
  • Psychology, Medicine
  • Neuroscience & Biobehavioral Reviews
  • 1996
The present paper reviews a series of experiments aimed at elucidating the interaction between specific dopamine (DA) and 5-hydroxytryptamine (5-HT) receptors in the mediation of extrapyramidal motorExpand
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
TLDR
Observations that NMDA receptor antagonists injected into the striatum or given systemically have the ability to act palliatively or prophylactically to alleviate levodopa-induced response alterations support the view that sensitization of striatal NMDA receptors contributes to the pathogenesis of motor dysfunction in Parkinson's disease. Expand
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
TLDR
Observations that NMDA receptor antagonists injected into the striatum or given systemically also have the ability to act palliatively or prophylactically to alleviate levodopa-induced response alterations support the view that sensitization of striatal NMDA receptors contributes to the pathogenesis of motor dysfunction in Parkinson's disease. Expand
Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum
TLDR
In vivo microdialysis data seem to indicate that increase in extracellular 5‐HT level and5‐HT1 and 5-HT2 receptor activation increase in vivo DA extrace cellular output in the striatum mainly by a non‐exocytotic mechanism involving DA uptake sites and, secondarily, by activation of 5‐ HT receptors. Expand
8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release
TLDR
It can be concluded that the anticataleptic effect of these compounds is not related to an alteration of DA release within the striatum, and both 5-HT agents failed to modify basal DA and DOPAC striatal outflow as well as the stimulatory effect of HAL on these parameters. Expand
Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats.
TLDR
With the exception of (-)-tertatolol, which behaved as a weak agonist, a very similar pattern of inhibition of 5-HT turnover was seen in the striatum, the hippocampus and the hypothalamus (DRN and median raphe nucleus) and the spinal cord, with the Striatum displaying the greatest sensitivity. Expand
Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
TLDR
It is hypothesize that the risk of developing motor complications in PD patients when levodopa is introduced can be reduced if the levdopa is coupled with a COMT inhibitor so as to provide more continuous dopaminergic stimulation of dopamine receptors. Expand
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms
TLDR
It appears that the denervation or intermittent stimulation of striatal dopaminergic receptors differentially activates signal transduction pathways in medium spiny neurons, which modify the phosphorylation state of ionotropic glutamate receptors and consequently their sensitivity to cortical input. Expand
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration
TLDR
It is suggested that the extent of a dopamine neuron loss must exceed a relatively high threshold before intermittent levodopa treatment produces changes favoring the rapid appearance of motor fluctuations of the wearing-off and on-off types. Expand
...
1
2
3
4
5
...